HealthDay News -- For intramuscular hepatitis
B virus vaccine nonresponders, intradermal vaccine administration seems
efficacious and safe, according to a study published in the Journal of Gastroenterology and Hepatology.
About 5% to 10% of people fail to develop a protective immune
response to hepatitis B virus (HBV) vaccination, which has important
implications for health care workers, families living in households with
people that have HBV, and others who may be at increased risk of
exposure to HBV.
So Or Kalchiem-Dekel, MD, from the Soroka University Medical Center
in Israel, and colleagues designed a prospective case series to examine
efficacy, safety, and durability of intradermal vaccine administration
in those who have not responded well to intramuscular HBV vaccine.
Read more...Labels: intradermal vaccine, vaccine nonresponders